文献速递肺外科

美国肺叶切除术的成本差异与医疗价值

Cost Variation and Value of Care in Pulmonary Lobectomy Across the United States.
PubMed 文献 · Ann Thorac Surg · 2022-05-05

基于2016至2018年全国再入院数据库,分析565家医院每年95 446例择期肺叶切除术的中心层面成本与质量差异。中位中心成本为22 000美元,中位不良结局率为14.3%;O/E比值定义的高价值中心占35.2%,低价值中心占18.6%。高价值中心治疗更年长、合并症更多的患者,但肺叶切除年手术量更大,且并发症和成本更低。

要点

  • 肺叶切除术中心层面成本与质量存在显著差异,高价值中心占35.2%,低价值中心占18.6%。
  • 不良事件O/E比值小于1的中心每例风险调整成本降低2200美元。
  • 高价值中心患者更年长(67.1岁 vs 65.5岁)、合并症更多(Elixhauser指数3.7 vs 2.9),但年手术量更大(40例 vs 30例)。

核心结论

  • 肺叶切除术在全国范围内成本和质量的显著差异持续存在。
  • 高价值项目虽然手术风险更高,但并发症和成本更低。
  • 作者认为需要推广质量改进和成本降低实践。

研究设计与样本

  • 回顾性队列研究,使用2016至2018年全国再入院数据库。
  • 纳入成人择期肺叶切除术患者,分析年手术量大于或等于10例的医院。
  • 共纳入95 446例患者,分布在565家医院。

主要发现

  • 中心层面肺叶切除术中位成本为22 000美元(四分位距18 000-27 000美元)。
  • 中位不良结局率为14.3%(四分位距8.3%-23.1%)。
  • 不良事件O/E比值小于1的中心每例风险调整成本降低2200美元。
  • 高价值中心占35.2%,低价值中心占18.6%。
  • 高价值中心较低价值中心患者更年长(67.1岁 vs 65.5岁,P < .001)、合并症更多(Elixhauser合并症指数3.7 vs 2.9,P < .001)、年肺叶切除量更大(40例 vs 30例,P = .001),且更多为教学医院。

关键数值与推荐

  • 高价值医院定义为成本O/E比值小于1且质量O/E比值小于1;低价值医院定义相反。
  • 质量定义为无主要不良结局,包括呼吸衰竭、急性肾损伤、再手术和死亡。

临床怎么用

  • 作者认为需要推广质量改进和成本降低实践。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Optimization of value, or quality relative to costs, has garnered significant attention in the United States. We aimed to characterize center-level variation in costs and quality after pulmonary lobectomy using a national cohort. METHODS: Adults undergoing elective pulmonary lobectomy were identified in the 2016 to 2018 Nationwide Readmissions Database. Quality was defined by the absence of major adverse outcomes including respiratory failure, acute kidney injury, reoperation, and death. Risk-adjusted adverse outcome rates and costs were studied for institutions performing greater than or equal to 10 operations annually. Using observed-to-expected (O/E) ratios, high-value hospitals were defined as those with an O/E ratio less than 1 for costs and O/E ratio less than 1 for quality, while low-value hospitals were defined by the converse. RESULTS: Among 95 446 patients managed at 565 hospitals annually, the median center-level cost for lobectomy was $22 000 (interquartile range, $18 000-$27 000), while the median adverse outcome rate was 14.3% (interquartile range, 8.3%-23.1%). Centers with an O/E ratio less than 1 for adverse events exhibited a $2200/case reduction in risk-adjusted costs. Using O/E ratios, 35.2% of centers were classified as high value while 18.6% were low value. Compared with low-value centers, high-value centers treated older patients (67.1 years of age vs 65.5 years of age; P < .001) with greater comorbidities (Elixhauser Comorbidity Index 3.7 vs 2.9; P < .001) but had greater annual lobectomy volume (40 cases vs 30 cases; P = .001) and were more commonly teaching hospitals. CONCLUSIONS: Significant variation in costs and quality persists for lobectomy at the national level. Although high-value programs operated on patients at greater surgical risk, they had reduced complications and costs. Our findings suggest the need for dissemination of quality improvement and cost reduction practices.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Hadaya J, Verma A, Haro G, et al. Cost Variation and Value of Care in Pulmonary Lobectomy Across the United States. Ann Thorac Surg. 2022. PMID: 35526606. doi:10.1016/j.athoracsur.2022.04.043

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。